{"id":"acemannan","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Adjuvants, Immunologic","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"carrisyn","offLabel":[],"synonyms":["acemannan aloe vera","acemannan","carrisyn","polymannoacetate"],"timeline":[],"brandName":"Carrisyn","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and Carrisyn is a key that fits into those locks. When it binds to the lock, it triggers a series of events that can help treat a particular disease or condition. This is a simplified explanation of how small molecules like Carrisyn work at a molecular level.","oneSentence":"Carrisyn works by interacting with a specific molecular target to produce a therapeutic effect.","technicalDetail":"Carrisyn's mechanism of action is not well understood, but it is believed to involve the inhibition of a specific enzyme or protein, leading to a cascade of downstream effects that ultimately result in a therapeutic response."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Acemannan","title":"Acemannan","extract":"Acemannan is a D-isomer mucopolysaccharide in aloe vera leaves. This compound has potential immunostimulant, antiviral, antineoplastic, and gastrointestinal properties."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2985","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ACEMANNAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACEMANNAN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Acemannan","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T07:27:28.921756","biosimilars":[],"competitors":[],"genericName":"acemannan","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03250923","phase":"PHASE1,PHASE2","title":"CelAgace™ OraRinse Solution for Treatment of Candidiasis","status":"UNKNOWN","sponsor":"CelaCare Technologies, Inc.","startDate":"2024-09","conditions":["Candidiasis, Oral"],"enrollment":15,"completionDate":"2025-05"},{"nctId":"NCT04481802","phase":"NA","title":"The Effect of RadiaAce Gel in the Prevention and Treatment of Radiation Dermatitis in Breast Cancer Patients","status":"UNKNOWN","sponsor":"AceTech","startDate":"2021-07-14","conditions":["Breast Cancer","Radiation Dermatitis"],"enrollment":120,"completionDate":"2022-10"},{"nctId":"NCT03808532","phase":"PHASE2","title":"Moisturizer to Prevent Atopic Dermatitis","status":"WITHDRAWN","sponsor":"MYOR Ltd.","startDate":"2020-06","conditions":["Dermatitis, Atopic"],"enrollment":0,"completionDate":"2022-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000179027","NDDF":"006859","UNII":"UZ29E6L2X8","VUID":"4020577","VANDF":"4020577","INN_ID":"6355","RXNORM":"1426875","UMLSCUI":"C0050408","ChEMBL_ID":"CHEMBL3989763","KEGG_DRUG":"D02781","PUBCHEM_CID":"72041","SNOMEDCT_US":"125724005","MESH_SUPPLEMENTAL_RECORD_UI":"C058414"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":144,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Oligosaccharide","firstApprovalDate":"","aiSummary":"Carrisyn, also known as ACEMANNAN, is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to determine its potential therapeutic applications and safety profile. The current owner of Carrisyn is not publicly disclosed.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}